Generic Name and Formulations:
Pyridostigmine bromide 5mg/mL; soln for IV inj; contains benzyl alcohol.
Indications for REGONOL:
As a reversal agent or antagonist to the neuromuscular blocking effects of nondepolarizing muscle relaxants.
Individualize. Give by IV inj. Usual range: 0.1–0.25mg/kg. Give atropine sulfate or equipotent dose of glycopyrrolate immediately prior to or simultaneously with Regonol.
Intestinal or urinary obstruction.
Bronchial asthma. Cardiac dysrhythmias. Electrolyte imbalance. Adrenal cortical insufficiency. Renal impairment. Neonates. Pregnancy (Cat.C).
Concomitant 4-aminopyridine may delay onset. Possible resistance to reversal with antibiotics associated with paralysis (eg, aminoglycosides, tetracyclines, bacitracin, polymyxin B, colistin, sodium colistimethate). Recurrent paralysis possible with quinidine. Magnesium salts may enhance neuromuscular blockade and interfere with restoration.
GI upset, increased salivation and bronchial secretions, miosis and diaphoresis, muscle cramps, fasciculation and weakness, rash.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|